FMX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FMX is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has decent longer-term structure and supportive analyst coverage, but the current technical momentum is mixed and there is no strong proprietary buy signal today. My direct view: hold and wait for a better entry rather than buying immediately.
FMX is trading at 120.85, essentially flat versus the previous close of 120.86. The trend structure is mixed: SMA_5 > SMA_20 > SMA_200 is bullish, but MACD histogram is -0.377 and negatively expanding, which signals weakening momentum. RSI_6 at 42.684 is neutral-to-soft, not oversold. Price is sitting near support at S1 120.235 and below the pivot 122.37, so the short-term setup is not strong enough to call an immediate buy. The pattern-based outlook suggests only modest near-term upside with some weakness in the next week.
No recent negative news was reported, and there are no concerning insider, hedge fund, or congress trading trends.
Momentum has weakened because the MACD histogram is negative and expanding. RSI is not showing strong accumulation. There was no news in the past week, so there is no immediate catalyst to push the stock higher. Hedge fund and insider activity are neutral, and there is no congress trading signal. The stock is also trading below the pivot level, which reduces the attractiveness of entering immediately.
No usable latest-quarter financial snapshot was provided due to a data error, so I cannot verify the most recent quarter season or confirm current revenue/earnings growth from the dataset. Based on the available information, there is no updated financial-quarter evidence strong enough to improve the buy case.
Recent analyst trend is positive but mixed. UBS upgraded its price target to $139 from $122 and maintains a Buy rating, which is the strongest bullish call in the set. Barclays also raised its target to $125 from $118 but keeps an Equal Weight rating, while JPMorgan raised its target to $117 from $98 and remains Neutral. Overall, Wall Street is somewhat constructive, but not unanimously bullish; the pros see valuation/upside potential, while the cautious camp is still only Neutral or Equal Weight.
